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A B S T R A C T
Purpose: Adverse effects of anti epileptic drugs (AEDs) can signiﬁcantly affect the life of people with
epilepsy. We used a register to determine if polytherapy with AED has more adverse effects than
monotherapy.
Methods: We established a register for people with epilepsy (www.UKAED.info). Participants were
requested to complete the Liverpool Adverse Event Proﬁle (LAEP) to quantify adverse effects. We also
recorded type of epilepsy, seizure control and AED including drug doses. Five hundred and seventy six
complete data sets were available, monotherapy (n = 186), polytherapy (n = 325) and control subjects
not taking AED (n = 65).
Results: The mean LAEP scores in polytherapy (45.56, conﬁdence interval (CI) = 44.36–46.76) were
signiﬁcantly higher than the mean LAEP scores in monotherapy (42.29, CI = 40.65–44.02) and the mean
LAEP scores in controls (33.25, CI = 31.05–35.44). Tiredness, memory problems and difﬁculty
concentrating were the most common symptoms in patients taking AED and were consistently higher
in polytherapy than in monotherapy. Tiredness was reported as always or sometimes being a problem in
(polytherapy/monotherapy/controls) 82.5%/75.6%/64.6%, memory problems in 76%/63.2%/29.2% and
difﬁculty concentrating in 68%/63.9%/30.8%. The proportion of seizure-free patients was signiﬁcantly
lower in the polytherapy group (17%) than in the monotherapy group (55%). Depression rates between
the monotherapy and polytherapy groups were similar. Drug dosages were higher in polytherapy,
however this did not reach statistical signiﬁcance.
Conclusion: Patients on polytherapy had signiﬁcantly higher LAEP scores than patients on monotherapy.
This should be carefully discussed with the patient before a second AED is added.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is one of the most common chronic neurological
diseases, usually requiring long term treatment with anti epileptic
drugs (AEDs). Epileptic seizures, additional co-morbidity and
adverse effects (AE) of AED can all greatly affect the quality of life of
those suffering from epilepsy.1 There are currently 25 licensed AED
on the market in the UK, which offer numerous combination
therapies. This provides a great challenge for the clinician when
deciding on a suitable treatment plan. Monotherapy is commonly
viewed as the ‘gold standard’ of pharmacological treatment.
However, with the introduction of so many new generation AED
with an ‘‘add on’’ license, polytherapy has became a reality forAbbreviations: AED, anti epileptic drug; AE, adverse effect; CBZ, Carbamazepine;
LTG, Lamotrigine; LEV, Levetiracetam; PHT, Phenytoin; VPA, Valproate; LAEP,
Liverpool Adverse Event Proﬁle; CLE, cryptogenic localisation related epilepsy; SLE,
symptomatic localisation related epilepsy; GE, generalised epilepsy; CI, conﬁdence
interval; SD, standard deviation.
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http://dx.doi.org/10.1016/j.seizure.2012.06.013many patients.2 A recent study from Norway showed that 18% of
patients were on polytherapy. The most common combinations
were Lamotrigine with Valproate and Levetiracetam with Carba-
mazepine.3
A number of studies compared the efﬁcacy and severity of AE
between polytherapy and monotherapy, however a general
consensus has not been achieved. Shorvon and Reynolds empha-
sised three major problems associated with polypharmacother-
apy: chronic toxicity, exacerbation of seizures and drug
interactions, therefore they strongly supported the use of high
dose monotherapy before employing add-on therapy.4 However,
the study had been carried out before the introduction of the newer
AED, which potentially could be safely employed in polytherapy.
Currently, little is known about the prevalence of AE including
cognitive and psychological disturbances caused by AED but the
prevalence is likely to be high.5 A study suggested that doctors may
under-report severe AE6 and doctors may miss or fail to report
milder symptoms even more frequently. Recording symptoms
directly from the patient may have advantages to assess AE and to
monitor AED in clinical practice. Our aim was to utilise the UKAED
Register, a self-referral register to compare the AE proﬁle of AED.
The register is based on the Liverpool Adverse Event Proﬁle (LAEP)vier Ltd. All rights reserved.
Fig. 1. Box plot showing Liverpool Adverse Event Proﬁle scores for controls, patients
on monotherapy and patients on polytherapy. The dark line within the box
represents the median, the end of the box fall at the upper and lower quartiles. The
whiskers were drawn from the lower and upper quartile to the data point, which
was still within 1.5 of the inter-quartile range.
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physical, psychological and cognitive state (Fig. 1).7–11
2. Methods
The UKAED Register is a prospective register to study the
efﬁcacy and side effects of AED. The register was established at The
Walton Centre for Neurology & Neurosurgery, Liverpool in July
2008. Anybody who takes AED can self-refer to the register. The
register is independent from the pharmaceutical industry and has
ethical approval. For the current analysis we included all subjects
with complete data sets. Subjects were divided in three groups:
monotherapy (patients on 1 AED), polytherapy (patients > 1 AED)
and control subjects. The control subjects were either employees at
The Walton Centre, students at Liverpool University or patients
with single seizures or very infrequent seizures not taking AED. All
the data was collected using the Liverpool Adverse Event Proﬁle
(LAEP) questionnaire, which was completed by the patients either
electronically via http://www.ukaed/info or in paper form in the
Mersey Regional Epilepsy clinic at The Walton Centre in Liverpool.
The variables recorded in LAEP included 19 self-reported
symptoms. These are rated by the patient/carer on the 4-point
Likert scale. 1 indicates the symptom is never a problem; 2, it is
rarely a problem; 3, it is sometimes a problem; and 4, always or
often a problem. Hence it is possible to analyse the scores of
individual symptoms as well as calculate overall symptom score.7–
9 The following features of the respondents were also recorded in
the questionnaire: gender, age, sex, seizure control, AED and their
dosages, epileptic syndrome and other co-morbidities. The data
was collected between July 2008 and August 2011. Initial number
of subjects was 601. After excluding patients based on insufﬁcient
amount of data and unanswered items of the questionnaire, the
ﬁnal number of subjects was 576: 65 controls, 186 monotherapy
and 325 polytherapy. Our patients were on a wide range of AED
including: Carbamazepine (CBZ), Valproate (VPA), Lamotrogine
(LTG), Phenytoin (PHT), Oxcarbazepine, Levetiracetam (LEV),
Clobazam (CLO), Topiramate (TPM), Primidone, Zonizamide
(ZNS), Gabapentin, Lacosomide, Clonazepam, Azetazolamide,
Ruﬁnamide, Pregabalin, Eslicarbazepine, Phenobarbitone, Vigaba-
trin, Diazepam, Nitrazepam, Lorazepam, Piracetam, Ethosuximide,Sulthiame, Pyridoxine. The total LAEP and individual symptom
scores were calculated and compared employing several statistical
tools including ANOVA, Bonferroni’s, Tukey’s and chi squared tests
on SPSS software. We also calculated the LAEP score of the
individual drugs (CBZ, VPA, LTG, LEV) as well as the four most
common drug combinations (CBZ with LEV, VPA with LEV, CBZ
with LTG, PHT with LEV). Furthermore, possible confounding
factors including depression and seizure control were assessed.11
Depression scores were compared amongst the groups along with
the drug dosages. The proportion of seizure-free patients was
calculated in monotherapy and polytherapy groups.
3. Results
The mean LAEP score was lowest in the control group (33.25,
conﬁdence interval (CI) 31.05–35.44). Signiﬁcantly higher mean
LAEP scores were observed in monotherapy 42.29 (CI 40.65–44.02)
and polytherapy 45.56 (CI 44.36–46.76). An ANOVA with
Bonferroni’s and Tukey’s tests showed signiﬁcant differences
between the three groups (p-value < 0.001).
For patients on monotherapy, we compared the most com-
monly used drugs CBZ, VPA, LEV and LTG. CBZ had the highest LAEP
score (n = 46, mean LAEP score 44.83, CI 41.68–47.97), followed by
LEV (n = 37 mean LAEP score 41.68, CI 37.95–45.40), LTG (n = 42,
mean LAEP score 40.05, CI 36.36–43.73) and VPA (n = 32, mean
LAEP score 40.03, CI 35.29–44.80) but the differences did not reach
statistical signiﬁcance.
Similar trends were observed in patients on polytherapy with
two AED. The lowest mean LAEP score was in patients on a
combination of LTG with CBZ (n = 5, mean LAEP score 40.00, CI
26.42–53.57). Higher scores were seen in combinations of CBZ
with LEV (n = 24, mean LAEP score 44.08, CI 39.83–48.32), LEV with
VPA (n = 13, mean LAEP score 44.38, CI 36.45–52.31), and LEV with
PHT (n = 8, mean LAEP score 44.50, CI 40.77–46.87). LEV was the
most commonly prescribed drug in combination therapy (n = 45).
Control subjects had the lowest mean LAEP score and
consistently scored lower in each individual subscore. Polytherapy
patients had higher LAEP subscores than monotherapy patients,
except for disturbed sleep and dizziness. The most common
symptoms were tiredness, memory problems and difﬁculty
concentrating in both monotherapy and polytherapy.
The frequencies in polytherapy/monotherapy/controls for
tiredness being always or sometimes occurring were 82.5%/
75.6%/64.6%, for memory problems always or sometimes occurring
76%/63.2%/29.2% and for difﬁculty concentrating always or
sometimes occurring 68%/63.9%/30.8%.
There was no signiﬁcant difference in the proportion of patients
with depression reported as always or sometimes being a problem
between monotherapy (42.3%) and polytherapy (48.1%). We
regarded the presence of depression if LAEP score was more than
2 (3 – sometimes a problem, 4 – always a problem). There was a
signiﬁcantly higher proportion of seizure-free patients in the
monotherapy group (54.3%) than polytherapy (16.6%). The mean
daily AED dose for CBZ, LTG, OXC, LEV, VPA were higher in
polytherapy than in monotherapy. The mean daily dose of PHT was
lower in polytherapy than in monotherapy. However, conﬁdence
intervals overlapped in all 6 AEDs.
4. Discussion
Our paper reﬂects modern day practice. Newer AED including
Keppra are used ever more readily. Using validated measures to
assess patient outcomes, we found statistically signiﬁcantly higher
rates of self-reported symptoms in the polytherapy group (mean
LAEP score 45.56, CI 44.36–46.76) compared to monotherapy
group (mean LAEP score 42.29, CI 40.65–44.02). Overall, adverse
Table 1
Clinical data and LAEP results.
Control Monotherapy Polytherapy
n 65 186 325
Sex (f/m) 37/28 120/66 183/142
Age [years] (SD) 31.35 (11.52) 39.47 (13.71) 42.93 (14.06)
CLE/SLE/GE/other n/a 76/35/67/8 104/84/122/15
CBZ/LTG/LEV/VPA/other n/a 46/42/37/32/31 117/118/156/72/(n/a)
Number of co-morbidities 2 64 163
Seizure-free rate [%]a n/a 54.3 16.3
LAEP scores (95%CI)a 33.25 (31.05–35.44) 42.29 (40.5–44.02) 45.56 (44.36–46.76)
Depression [%]b n/a 42.3 48.1
Tiredness [%]b 64.6 75.6 82.5
Memory problems [%]b 29.2 63.2 76.0
Difﬁculty concentrating [%]b 30.8 63.9 68
CLE/SLE/GE = cryptogenic localisation related epilepsy/symptomatic localisation related epilepsy/generalised epilepsy, CI = conﬁdence interval.
a The differences between mono and polytherapy were statistically signiﬁcant.
b Symptoms were reported as always or sometimes being a problem.
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supports pre-existing evidence.4,12,13 Our observation that poly-
therapy causes more side effects than monotherapy was consistent
with the results of Namazi et al.14 and Haag et al.1 In addition,
Thomas et al.12 showed that polytherapy was associated with
lower quality of life while Haag et al.1 implicated worse
employment opportunities in patients on multiple AEDs. In
contrast, a single randomised controlled trial (RCT) failed to show
any signiﬁcant difference,15 however, patients were only on one or
two old drugs (CBZ versus CBZ and VPA), whereas in our study
patients were on numerous combinations typically including at
least one new AED (Table 1).
It is also worth noting that in our study the LAEP scores in the
polytherapy group were often above 45, which is considered
intoxication according to Gilliam et al.7 The mean LAEP was >45 in
the polytherapy group. The three most common symptoms
reported in our study were all central nervous system (CNS)
related and included: tiredness, memory problems and difﬁculty
concentrating. The frequencies of reported AE were very high in
both polytherapy and monotherapy, although higher in poly-
therapy. More than 80% in the polytherapy group and more that
three quarters in the monotherapy group complained about
tiredness, more than three quarters in the polytherapy group and
almost two thirds of patients complained about memory problems
and about two thirds in both groups complained about difﬁculties
concentrating as always or at least sometimes being a problem.
Our data is in keeping with the results of Carpay et al.,5 who
reported almost 60% of patients had CNS related AE. Depression
and uncontrolled epilepsy were identiﬁed as confounding fac-
tors.11,13 A higher prevalence of depression in patients on AED than
in control subjects may explain the higher LAEP scores in patients
on AED compared to controls but is unlikely to explain the higher
LAEP scores in polytherapy compared to monotherapy because the
depression rates were very similar in poly and monotherapy (48.7%
and 42.3%, respectively). Uncontrolled epilepsy in the polytherapy
group may have affected the result. Nevertheless, our data
highlights the burden of AED. Doctors should resist the temptation
to over-treat patients. However, any symptom should not
automatically be regarded as an AE of AED in patients with
depression and uncontrolled epilepsy. Patients should be encour-
aged to take AED regularly as non-adherence may be associated
with an increased mortality unless it is certain that symptoms are
caused by the AED.16
In addition to our main comparison of poly and monotherapy
we performed a subgroup analysis looking for differences in
different AED. The result should be interpreted with caution but
showed interesting trends. In our study CBZ (n = 46, mean LAEP
score 44.83, CI 41.68–47.97) was the least well toleratedmonotherapy AED but the conﬁdence intervals overlapped with
other AED used in monotherapy. The LAEP score of CBZ in
combination with LEV (n = 24, mean = 44.08, CI = 39.83–48.32)
was not higher than in CBZ monotherapy. Interestingly CBZ with
LTG had a lower mean LAEP (n = 5, mean = 40.00, CI = 26.42–53.57)
than CBZ in monotherapy but the numbers were too small to draw
any ﬁrm conclusions. We showed a trend for LTG having less AE but
this did not reach signiﬁcance, potentially because of the small
numbers. According to the SANAD trial LTG is better than CBZ
largely because of the better AE proﬁle of LTG.17 Brodie et al. also
reported that LTG is better tolerated than CBZ.18
Our approach to use a self-referral register to assess possible AE
of AED has a number of limitations. Recorded symptoms are
reported by patients and have to be taken on trust. The data in the
register may be biased towards more severe cases. Controls were
not matched to cases and the mean age in controls was lower than
in patients on AED. Polytherapy patients had more severe epilepsy
than monotherapy in our study, frequent seizures were likely to be
a confounding factor. In addition, there was a trend for higher AED
doses in polytherapy than in monotherapy. There are numerous
possible combinations for polytherapy. In the current analysis the
numbers for each combination were too small to be certain that
there are differences between the polytherapies. We hope that
with increasing numbers of patients we will be able to provide
more robust data on individual combination therapies. The register
cannot replace a RCT. Having said this, we think that a register adds
to the body of evidence of the burden on AED. We think that the
information from the register was valuable and perhaps even more
applicable because the AED used reﬂected current clinical practice.
In summary, polytherapy had signiﬁcantly higher LAEP scores
than monotherapy. This should be discussed with the patient
before a second AED is added.
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